drugset / Trial / NCT07154485
Investigator Initiated Study for the Safety and Efficacy in Frontotemporal Dementia
Phase 2
Not yet recruiting
15 enrolled
Hee-Jin Kim
Asan Medical Center · collabGangnam Severance Hospital · collabKonkuk University Medical Center · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics (PK/PD), immunogenicity, and efficacy of multiple intravenous administrations of the investigational drug NS101, compared to placebo, in patients with semantic variant primary progressive aphasia (svPPA), a subtype of frontotemporal dementia (FTD)
Timeline
- Start
- 2025-10-01
- Primary completion
- 2027-08-01
- Completion
- 2028-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | NS101 | Monoclonal antibody | 15 mg/kg | Intravenous |